Charles Schwab Investment Management Inc. Sells 247,868 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Charles Schwab Investment Management Inc. cut its holdings in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 15.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,367,345 shares of the company's stock after selling 247,868 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.59% of Pediatrix Medical Group worth $15,848,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Rubric Capital Management LP increased its holdings in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock valued at $61,532,000 after acquiring an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after purchasing an additional 455,785 shares during the last quarter. Brandes Investment Partners LP raised its position in shares of Pediatrix Medical Group by 12.8% in the second quarter. Brandes Investment Partners LP now owns 735,068 shares of the company's stock valued at $5,438,000 after purchasing an additional 83,588 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company's stock worth $5,953,000 after buying an additional 63,581 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in shares of Pediatrix Medical Group by 0.5% during the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company's stock worth $3,196,000 after buying an additional 2,083 shares during the period. 97.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MD has been the topic of a number of research analyst reports. Mizuho raised their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research note on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft raised their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research report on Monday, November 4th. StockNews.com cut Pediatrix Medical Group from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Truist Financial raised their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a report on Monday, November 4th. Finally, UBS Group lifted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of "Hold" and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

MD stock traded up $0.10 during trading on Friday, reaching $14.80. 404,429 shares of the stock were exchanged, compared to its average volume of 672,218. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.27 billion, a P/E ratio of -4.84, a price-to-earnings-growth ratio of 2.11 and a beta of 1.57. The stock has a 50 day simple moving average of $13.73 and a 200-day simple moving average of $10.54.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 EPS. As a group, sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mark S. Ordan sold 27,600 shares of the company's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares of the company's stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company's stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.